drugset
drugset / Trial / NCT02658214

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

NCT02658214 ↗

Phase 1 Completed 32 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Durvalumab and Tremelimumab in combination with first-line chemotherapy in the following indications: Ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC and gastric/GEJ cancer, PDAC, ESCC.

Timeline

Start
2016-04-28
Primary completion
2019-11-14
Completion
2019-11-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule — Intravenous
Subject Cisplatin Other / unclassified 80 mg/m2 Intravenous
Subject Durvalumab Monoclonal antibody 1500 mg Intravenous
Subject Etoposide Small molecule — Intravenous
Subject Gemcitabine Small molecule — Intravenous
Subject Leucovorin Small molecule — Intravenous
Subject Nab-paclitaxel Small molecule — Intravenous
Subject Oxaliplatin Small molecule — Intravenous
Subject Paclitaxel Small molecule — Intravenous
Subject Tremelimumab Monoclonal antibody 75 mg Intravenous
Subject fluorouracil Small molecule 800 mg/m2 Intravenous

Indications

esophageal squamous cell carcinoma fallopian tube neoplasm gastric neoplasm gastroesophageal cancer head and neck squamous cell carcinoma ovarian neoplasm pancreatic ductal adenocarcinoma peritoneal neoplasm small cell lung carcinoma triple-negative breast carcinoma